TY - JOUR
T1 - Exercise therapy for fatigue in multiple sclerosis
AU - Heine, Martin
AU - Rietberg, Marc B.
AU - Amaral Gomes, Elvira
AU - Evenhuis, Ernst
AU - Beckerman, Heleen
AU - van de Port, Ingrid
AU - de Groot, Vincent
AU - Kwakkel, Gert
AU - van Wegen, Erwin E. H.
N1 - Funding Information: Editorial and peer-reviewer contributions The following people conducted the editorial process for this article: Sign-off Editor (final editorial decision): Robert Boyle, Cochrane’s Editorial Board, Imperial College London, UK Managing Editor (provided editorial guidance to authors): Ben Ridley, Multiple Sclerosis & Rare Diseases Cochrane group Managing Editor (selected peer reviewers, collated peer-reviewer comments, provided editorial guidance to authors, edited the article): Sam Hinsley, Central Editorial Service Editorial Assistant (conducted editorial policy checks and supported editorial team): Leticia Rodrigues, Central Editorial Service Copy Editor (copy editing and production): Cochrane Central Production Service Peer-reviewers (provided comments and recommended an editorial decision): Amy Drahota, University of Portsmouth (methods), Ina Monsef (search), Miguel Adriano Sanchez-Lastra, Norwegian School of Sports Sciences, Department of Sports Medicine, and University of Vigo, Department of Special Didactics (clinical), Bardia Nourbakhsh, Johns Hopkins University (clinical), Nicole Micklem (consumer) Sign-off Editor (final editorial decision): Robert Boyle, Cochrane’s Editorial Board, Imperial College London, UK Managing Editor (provided editorial guidance to authors): Ben Ridley, Multiple Sclerosis & Rare Diseases Cochrane group Managing Editor (selected peer reviewers, collated peer-reviewer comments, provided editorial guidance to authors, edited the article): Sam Hinsley, Central Editorial Service Editorial Assistant (conducted editorial policy checks and supported editorial team): Leticia Rodrigues, Central Editorial Service Copy Editor (copy editing and production): Cochrane Central Production Service Peer-reviewers (provided comments and recommended an editorial decision): Amy Drahota, University of Portsmouth (methods), Ina Monsef (search), Miguel Adriano Sanchez-Lastra, Norwegian School of Sports Sciences, Department of Sports Medicine, and University of Vigo, Department of Special Didactics (clinical), Bardia Nourbakhsh, Johns Hopkins University (clinical), Nicole Micklem (consumer) Publisher Copyright: Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2022/12/12
Y1 - 2022/12/12
N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. Primary objectives The primary objectives of this review are as follows. 1.1 To determine the immediate (i.e. postintervention; 1.1a) and long-term (i.e. follow-up; 1.1b) benefits of exercise therapy, when compared to a control group, on self-reported fatigue in people with MS; and 1.2 To specifically determine the immediate and long-term benefits of exercise therapy, when compared to a control group, on self-reported fatigue when only clinical trials are considered in which (1.2a) self-reported fatigue was the primary outcome and (1.2b) only people with MS with predefined levels of self-reported fatigue were included. Secondary objectives The following secondary objectives will be pursued; each relevant to people with MS, clinicians and academics. Safety 2.1 To determine the safety of exercise therapy, when compared to a control group, as determined by an exploratory review of reported adverse effects over the course of the intervention phase. 2.2 To confirm the safety of exercise therapy, when compared to a control group, as determined by a confirmatory review of reported MS exacerbations, falls, and overuse injuries over the course of the intervention phase. Intervention characteristics 3.1 Determine the immediate and long-term differential impact of different exercise therapy modalities on self-reported fatigue (e.g. aerobic training). 3.2 Explore the relationship between dose of exercise therapy (an agglomeration of frequency, time per session, and program duration) and the immediate and long-term benefits of exercise therapy on fatigue. 3.3 Explore the relationship between features of exercise therapy programs (e.g. progression, overload, specificity) and the immediate and long-term benefits of exercise therapy on fatigue. Participant characteristics 4.1 Determine the impact of baseline fatigue levels on the immediate and long-term benefits of exercise therapy on fatigue. 4.2 Determine the impact of baseline levels of disease severity (i.e. Expanded Disability Status Scale [EDSS]) on the immediate and long-term benefits of exercise therapy on fatigue. Study design characteristics 5.1 Determine the impact of the specific self-reported fatigue measure (e.g. Fatigue Severity Scale) on the immediate and long-term benefits of exercise therapy on fatigue. 5.2 Determine the impact of methodological quality (i.e. risk of bias) and (self-reported) pilot studies, on the immediate and long-term benefits of exercise therapy on fatigue. 5.3. Determine the impact of the type of control group on the immediate and long-term benefits of exercise therapy on fatigue.
AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. Primary objectives The primary objectives of this review are as follows. 1.1 To determine the immediate (i.e. postintervention; 1.1a) and long-term (i.e. follow-up; 1.1b) benefits of exercise therapy, when compared to a control group, on self-reported fatigue in people with MS; and 1.2 To specifically determine the immediate and long-term benefits of exercise therapy, when compared to a control group, on self-reported fatigue when only clinical trials are considered in which (1.2a) self-reported fatigue was the primary outcome and (1.2b) only people with MS with predefined levels of self-reported fatigue were included. Secondary objectives The following secondary objectives will be pursued; each relevant to people with MS, clinicians and academics. Safety 2.1 To determine the safety of exercise therapy, when compared to a control group, as determined by an exploratory review of reported adverse effects over the course of the intervention phase. 2.2 To confirm the safety of exercise therapy, when compared to a control group, as determined by a confirmatory review of reported MS exacerbations, falls, and overuse injuries over the course of the intervention phase. Intervention characteristics 3.1 Determine the immediate and long-term differential impact of different exercise therapy modalities on self-reported fatigue (e.g. aerobic training). 3.2 Explore the relationship between dose of exercise therapy (an agglomeration of frequency, time per session, and program duration) and the immediate and long-term benefits of exercise therapy on fatigue. 3.3 Explore the relationship between features of exercise therapy programs (e.g. progression, overload, specificity) and the immediate and long-term benefits of exercise therapy on fatigue. Participant characteristics 4.1 Determine the impact of baseline fatigue levels on the immediate and long-term benefits of exercise therapy on fatigue. 4.2 Determine the impact of baseline levels of disease severity (i.e. Expanded Disability Status Scale [EDSS]) on the immediate and long-term benefits of exercise therapy on fatigue. Study design characteristics 5.1 Determine the impact of the specific self-reported fatigue measure (e.g. Fatigue Severity Scale) on the immediate and long-term benefits of exercise therapy on fatigue. 5.2 Determine the impact of methodological quality (i.e. risk of bias) and (self-reported) pilot studies, on the immediate and long-term benefits of exercise therapy on fatigue. 5.3. Determine the impact of the type of control group on the immediate and long-term benefits of exercise therapy on fatigue.
UR - http://www.scopus.com/inward/record.url?scp=85143816655&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/14651858.CD015274
DO - https://doi.org/10.1002/14651858.CD015274
M3 - Article
SN - 1464-780X
VL - 2022
JO - Cochrane Library
JF - Cochrane Library
IS - 12
M1 - CD015274
ER -